Interestingly, collating data from seven different cohorts of melanoma patients treated with ICBT revealed that patients treated firstly with anti-CTLA4 followed by anti-PD-1 who displayed high IFN-γ signalling in tumour biopsies responded best to ICBT [39]. This evidence concerns the gene CTLA4 and neoplasm.